Immune Response News and Research

RSS

Differential NK cell activity found to contribute to SARS-CoV-2 infection resistance

The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected millions of people worldwide and is the leading cause of mortality in Brazil in 2020 as well as early 2021. Clinical manifestations of COVID-19 disease range from no symptoms and mild flu-like symptoms to severe cases leading to hospitalization and death.

3 May 2021

Researchers demonstrate real-world effectiveness of Johnson & Johnson COVID-19 vaccine

Researchers in the United States and India have conducted a study demonstrating the real-world effectiveness of a single dose of Johnson & Johnson’s Ad26.COV2.S vaccine at preventing infection with severe acute respiratory syndrome coronavirus 2 – the agent that causes coronavirus disease 2019 (COVID-19).

3 May 2021

SARS-CoV-2 antibodies are detectable up to a year after infection, finds study

A team of scientists from the United States has recently investigated the robustness and durability of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in coronavirus disease 2019 (COVID-19) patients. Their findings reveal that COVID-19 patients exhibit a strong anti-SARS-CoV-2 antibody response for up to 1 year and that the robustness of antibody response depends on the patient’s age and disease severity.

3 May 2021

Class I HLA alleles shape CD8+ T cell repertoire in SARS-CoV-2 infection

An interesting new study discusses how adaptive cellular immunity against the SARS-CoV-2 is dependent on differences in HLA-encoding genes between patients.

3 May 2021

Vaccine candidate targeting SARS-CoV-2 nucleocapsid protein elicits protective immune response in animal model

New preclinical results from a study led by David Masopust of the University of Minnesota in Minneapolis, USA, show that a Had5-based vaccine targeting the nucleocapsid protein can also elicit a protective immune response.

3 May 2021

Competitive multiplex binding assay can monitor SARS-CoV-2 immune responses using nanobodies

Researchers at the Eberhard Karls University and the University of Tübingen in Germany described 11 unique nanobodies (Nbs) specific for the SARS-CoV-2 spike receptor-binding domain (RBD), of which 8 Nbs potentially inhibit the connection of RBD with the angiotensin-converting enzyme 2 (ACE2).

3 May 2021

Live "attenuated" influenza virus vaccine protects animals against respiratory infections, including SARS-CoV-2

Researchers in the United States and Austria have demonstrated the potential of a modified influenza virus as a vaccine to protect against viral respiratory pathogens, including the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19).

2 May 2021

Researchers identify important factor in the development of dendritic cells

The human immune system comprises functionally specialized cellular defense mechanisms that protect the body against disease. These include the dendritic cells.

30 Apr 2021

Single dose of vaccine boosts protection only in people previously infected by COVID-19

A single dose of vaccine boosts protection against SARS-CoV-2 coronavirus variants, but only in those with previous COVID-19, a study has found.

30 Apr 2021

Applications of nanoparticles in combating COVID-19

Researchers review the various properties and use of nanoparticles in targeting SARS-CoV-2 and how they could be used to develop new therapeutics and diagnostics for SARS-CoV-2.

30 Apr 2021

Is Hong Kong’s fourth wave of COVID-19 due to the Q57H SARS-CoV-2 variant?

A recent article in the Centers for Disease Control and Prevention (CDC)’s Emerging Infectious Diseases reveals that the last of these was probably due to the introduction of a new variant from Nepal. This novel variant had been circulating in the community for about a month before the last outbreak was reported.

29 Apr 2021

Researchers discover how SARS-CoV-2 hijacks human cell machinery to blunt immune response

Researchers at University of California San Diego School of Medicine have discovered one way in which SARS-CoV-2, the coronavirus that causes COVID-19, hijacks human cell machinery to blunt the immune response, allowing it to establish infection, replicate and cause disease.

29 Apr 2021

New exosome-based therapeutic strategy to potentially treat late-stage colorectal cancer

In a recent discovery by University of Minnesota Medical School, researchers uncovered a new way to potentially target and treat late-stage colorectal cancer - a disease that kills more than 50,000 people each year in the United States.

29 Apr 2021

Study examines mRNA COVID-19 vaccine’s effectiveness across age and gender

The findings reveal that although the two-dose vaccine regimen initially induces robust antibody response in all age groups, older male individuals are particularly associated with a gradual decline in vaccine-induced immunity six weeks after the second vaccine dose.

28 Apr 2021

Can control theory explain differences in virulence and transmission of SARS-CoV-2?

A new study discusses variations in viral pathogenicity and in transmission, which are responsible for asymptomatic infection and for superspreading events. The ability to understand this would open the way to understand how this virus behaves the way it does, in terms of its virulence, its spread, and its emergent variants of concern.

28 Apr 2021

Peptide nucleocapsid vaccine candidate elicits protective T cell immunity against SARS-CoV-2 in vivo

A new study describes a synthetic peptide used as a platform to generate protective adaptive cellular immunity to the virus in rhesus macaques, which are the gold standard for preclinical testing in humans.

28 Apr 2021

You don’t have to suffer to benefit from Covid vaccination — but some prefer it

If you think vaccination is an ordeal now, consider the 18th-century version. After having pus from a smallpox boil scratched into your arm, you would be subject to three weeks of fever, sweats, chills, bleeding and purging with dangerous medicines, accompanied by hymns, prayers and hell-fire sermons by dour preachers.

28 Apr 2021

Scientists identify blood cells most likely to be targeted by HIV during a real-life infection

In the 40-some years since the beginning of the HIV/AIDS epidemic, scientists have learned a lot about the virus, the disease, and ways to treat it. But one thing they still don't completely understand is which exact cells are most susceptible to HIV infection.

28 Apr 2021

Study reveals the role of lncRNAs in immune dysfunction during severe COVID-19

Scientific studies rarely focus on long non-coding RNA molecules (lncRNAs), even though they potentially regulate several diseases. The role of several lncRNAs in anti-viral inflammatory response regulation has recently been reported.

28 Apr 2021

What is the role of nanotechnology in the current COVID-19 outbreak?

The nanotechnology-based medicine platforms against COVID-19 bears hope for relief from the pandemic to save lives and mitigate the infection as part of a broader global public health agenda.

27 Apr 2021

Immune Response News and Research

Differential NK cell activity found to contribute to SARS-CoV-2 infection resistance

Researchers demonstrate real-world effectiveness of Johnson & Johnson COVID-19 vaccine

SARS-CoV-2 antibodies are detectable up to a year after infection, finds study

Class I HLA alleles shape CD8+ T cell repertoire in SARS-CoV-2 infection

Vaccine candidate targeting SARS-CoV-2 nucleocapsid protein elicits protective immune response in animal model

Competitive multiplex binding assay can monitor SARS-CoV-2 immune responses using nanobodies

Live "attenuated" influenza virus vaccine protects animals against respiratory infections, including SARS-CoV-2

Researchers identify important factor in the development of dendritic cells

Single dose of vaccine boosts protection only in people previously infected by COVID-19

Applications of nanoparticles in combating COVID-19

Is Hong Kong’s fourth wave of COVID-19 due to the Q57H SARS-CoV-2 variant?

Researchers discover how SARS-CoV-2 hijacks human cell machinery to blunt immune response

New exosome-based therapeutic strategy to potentially treat late-stage colorectal cancer

Study examines mRNA COVID-19 vaccine’s effectiveness across age and gender

Can control theory explain differences in virulence and transmission of SARS-CoV-2?

Peptide nucleocapsid vaccine candidate elicits protective T cell immunity against SARS-CoV-2 in vivo

You don’t have to suffer to benefit from Covid vaccination — but some prefer it

Scientists identify blood cells most likely to be targeted by HIV during a real-life infection

Study reveals the role of lncRNAs in immune dysfunction during severe COVID-19

What is the role of nanotechnology in the current COVID-19 outbreak?

Understanding the DNA Damage Response in Innate Immunity eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News